eli lilly glp 1 drug Oral GLP-1 Orforglipron Is Approved for Obesity Novo, Lilly weight-loss drugs should
Description
Counting the days since you had your last poop? Oof
other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome
Obesity and Type 2 diabetes represent global health challenges, and there is an unmet need for long-lasting and effective pharmacotherapies
The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
)
GLP-1 receptor agonists such as semaglutide and tirzepatide support weight loss and blood sugar control by increasing satiety and improving glucose regulation
